[{"orgOrder":0,"company":"Evive Biotech","sponsor":"Peking University Cancer Hospital & Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Recombinant Anti-CD19\/CD3 Bispecific Antibody","moa":"CD19\/CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Evive Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evive Biotech \/ Peking University Cancer Hospital & Institute","highestDevelopmentStatusID":"6","companyTruncated":"Evive Biotech \/ Peking University Cancer Hospital & Institute"},{"orgOrder":0,"company":"Evive Biotech","sponsor":"Aurobindo Pharma Limited","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"INDIA","productType":"Protein","year":"2022","type":"Licensing Agreement","leadProduct":"Benegrastim","moa":"Granulocyte colony stimulating factor receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Evive Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evive Biotech \/ Evive Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Evive Biotech \/ Evive Biotech"},{"orgOrder":0,"company":"Evive Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"F-627","moa":"Granulocyte colony stimulating factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Evive Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evive Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Evive Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Evive Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"F-627","moa":"Granulocyte colony stimulating factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Evive Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evive Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Evive Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Evive Biotech","sponsor":"Fudan University","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"F-627","moa":"Granulocyte colony stimulating factor receptor","graph1":"Hematology","graph2":"Phase II","graph3":"Evive Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evive Biotech \/ Fudan University","highestDevelopmentStatusID":"8","companyTruncated":"Evive Biotech \/ Fudan University"},{"orgOrder":0,"company":"Evive Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"F-627","moa":"Granulocyte colony stimulating factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Evive Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evive Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Evive Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Evive Biotech","sponsor":"Fudan University | Affiliated Cancer Hospital & Institute of Guangzhou Medical University | Nanfang Hospital, Southern Medical University | The Affiliated Hospital of Qingdao University | Tongji Hospital | The Affiliated Tumor Hospital of Nantong Universi","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"F-627","moa":"Granulocyte colony stimulating factor receptor","graph1":"Hematology","graph2":"Phase II","graph3":"Evive Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evive Biotech \/ Fudan University | Affiliated Cancer Hospital & Institute of Guangzhou Medical University | Nanfang Hospital, Southern Medical University | The Affiliated Hospital of Qingdao University | Tongji Hospital | The Affiliated Tumor Hospital of Nantong Universi","highestDevelopmentStatusID":"8","companyTruncated":"Evive Biotech \/ Fudan University | Affiliated Cancer Hospital & Institute of Guangzhou Medical University | Nanfang Hospital, Southern Medical University | The Affiliated Hospital of Qingdao University | Tongji Hospital | The Affiliated Tumor Hospital of Nantong Universi"},{"orgOrder":0,"company":"Evive Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"F-627","moa":"Granulocyte colony stimulating factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Evive Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evive Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Evive Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Evive Biotech","sponsor":"Fudan University | Sun Yat-sen University","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"F-627","moa":"Granulocyte colony stimulating factor receptor","graph1":"Hematology","graph2":"Phase II","graph3":"Evive Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evive Biotech \/ Fudan University | Sun Yat-sen University","highestDevelopmentStatusID":"8","companyTruncated":"Evive Biotech \/ Fudan University | Sun Yat-sen University"},{"orgOrder":0,"company":"Evive Biotech","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"F-652","moa":"IL22 Receptor","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Evive Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Evive Biotech \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Evive Biotech \/ Memorial Sloan Kettering Cancer Center"},{"orgOrder":0,"company":"Evive Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"F-652","moa":"IL22 Receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Evive Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evive Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Evive Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Evive Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"F-652","moa":"IL22 Receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Evive Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evive Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Evive Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Evive Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Efbemalenograstim Alpha","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Evive Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evive Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Evive Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Evive Biotech","sponsor":"Nona Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Evive Biotech","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evive Biotech \/ Nona Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"Evive Biotech \/ Nona Biosciences"}]

Find Clinical Drug Pipeline Developments & Deals by Evive Biotech

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : The collaboration aims to accelerate the process of antibody discovery and drug development based on the Harbour Mice® antibody technology platform of Nona Biosciences.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          December 10, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Technology

                          Highest Development Status : Discovery

                          Sponsor : Nona Biosciences

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Under the terms of the agreement, Evive will be responsible for the ongoing development, manufacturing, registration, and supply of Ryzneuta (benegrastim), while Acrotech will use its sales and commercialisation capabilities to market and distribute the ...

                          Product Name : Ryzneuta

                          Product Type : Protein

                          Upfront Cash : Undisclosed

                          November 23, 2022

                          Lead Product(s) : Benegrastim

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase III

                          Recipient : Aurobindo Pharma Limited

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          03

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : F-652 is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          January 25, 2022

                          Lead Product(s) : F-652

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : F-652 is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          August 04, 2020

                          Lead Product(s) : F-652

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Safety and efficacy endpoints met successfully in pivotal trial for F-627 (efbemalenograstim alfa), a novel long-acting G-CSF . F-627 has proven that it is at least as efficacious and safe as NEULASTA®, which is the current standard of care.

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          July 08, 2020

                          Lead Product(s) : Efbemalenograstim Alpha

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : F-627 is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Breast Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          November 22, 2019

                          Lead Product(s) : F-627

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Lead Product(s) : Recombinant Anti-CD19/CD3 Bispecific Antibody

                          Therapeutic Area : Oncology

                          Study Phase : Phase I

                          Sponsor : Peking University Cancer Hospital & Institute

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Recombinant Anti-CD19/CD3 Bispecific Antibody is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lymphoma, B-Cell.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          August 14, 2019

                          Lead Product(s) : Recombinant Anti-CD19/CD3 Bispecific Antibody

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Peking University Cancer Hospital & Institute

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : F-627 is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Breast Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          August 17, 2017

                          Lead Product(s) : F-627

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : F-627 is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Breast Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          August 19, 2016

                          Lead Product(s) : F-627

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : F-627 is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neutropenia.

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          August 19, 2015

                          Lead Product(s) : F-627

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase I

                          Sponsor : Fudan University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank